Idella Struk
Family · Tallahassee, FLNPI 1336218791
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,870 of the $6,031 with a category attached, or 80.8%. 44 manufacturers reported payments, led by Livanova USA, Inc. at 30.0% of the total. Reporting peaked in 2022 at $2,476 and has fallen 97.2% since, to $68 in 2024. Among family clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 235 payments — averaging $25.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Livanova USA, Inc.$2K
- AbbVie$589
- SK Life Science, Inc.$460
- Jazz Pharmaceuticals Inc.$296
- Neurelis, Inc.$284
- Lundbeck LLC$242
- plus $2K from 38 others
What the payments were for
- Speaking & faculty fees$160%
- Travel & lodging$1,14419%
- Food & beverage$4,87081%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS - Sentiva$1,277
- VNS Therapy$532
- Omnia$137
- VALTOCO$118
- VYVGART$111
- INGREZZA$107
- XCOPRI$102
How this compares
$6,031 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UbrelvyUbrogepant | 32 | $39,302 |
| Aimovig AutoinjectorErenumab-Aooe | 24 | $18,881 |
| Emgality PenGalcanezumab-Gnlm | 16 | $10,666 |
| Levetiracetam | 56 | $2,445 |
| Gabapentin | 89 | $1,791 |
| Memantine Hcl | 51 | $1,304 |
| Duloxetine Hcl | 16 | $969 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 35 | $815 |
| Donepezil Hcl | 60 | $545 |
| Zonisamide | 15 | $411 |
| Topiramate | 11 | $70 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy | $589 | $39,30232 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.
Other family in Tallahassee
- Kathleen WilsonTallahassee$154K
- Brittany YatesTallahassee$73K
- Lewis HarringtonTampa$954K
- Danielle PharesFt Lauderdale$713K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
- Deena RodneyMaitland$323K
- Yamila MelendezMiami$212K
- Holly BoydLand O Lakes$200K
- Rachael BuschLoxahatchee$189K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.